Giant cell arteritis: A population-based retrospective cohort study exploring incidence and clinical presentation in Canterbury, Aotearoa New Zealand
- PMID: 36482913
- PMCID: PMC9723338
- DOI: 10.3389/fmed.2022.1057917
Giant cell arteritis: A population-based retrospective cohort study exploring incidence and clinical presentation in Canterbury, Aotearoa New Zealand
Abstract
Background/aim: To determine the epidemiology and clinical features of giant cell arteritis (GCA) in Canterbury, Aotearoa New Zealand, with a particular focus on extra-cranial large vessel disease.
Methods: Patients with GCA were identified from radiology and pathology reports, outpatient letters and inpatient hospital admissions in the Canterbury New Zealand from 1 June 2011 to 31 May 2016. Data was collected retrospectively based on review of electronic medical records.
Results: There were 142 cases of GCA identified. 65.5% of cases were female with a mean age of 74.2 years. The estimated population incidence for biopsy-proven GCA was 10.5 per 100,000 people over the age of 50 and incidence peaked between 80 and 84 years of age. 10/142 (7%) people were diagnosed with large vessel GCA, often presenting with non-specific symptoms and evidence of vascular insufficiency including limb claudication, vascular bruits, blood pressure and pulse discrepancy, or cerebrovascular accident. Those with limited cranial GCA were more likely to present with the cardinal clinical features of headache and jaw claudication. Patients across the two groups were treated similarly, but those with large vessel disease had greater long-term steroid burden. Rates of aortic complication were low across both groups, although available follow-up data was limited.
Conclusion: This study is the first of its kind to describe the clinical characteristics of large vessel GCA in a New Zealand cohort. Despite small case numbers, two distinct subsets of disease were recognized, differentiating patients with cranial and large vessel disease. Our results suggest that utilization of an alternative diagnostic and therapeutic approach may be needed to manage patients with large vessel disease.
Keywords: epidemiology; giant cell arteritis; incidence; large vessel vasculitis (LVV); vasculitis.
Copyright © 2022 Lyne, Ruediger, Lester, Chapman, Shanahan, Hill and Stamp.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study.Semin Arthritis Rheum. 2021 Aug;51(4):786-792. doi: 10.1016/j.semarthrit.2021.06.001. Epub 2021 Jun 7. Semin Arthritis Rheum. 2021. PMID: 34148007
-
HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study.Arthritis Res Ther. 2021 Sep 13;23(1):238. doi: 10.1186/s13075-021-02618-4. Arthritis Res Ther. 2021. PMID: 34517892 Free PMC article.
-
An Unusual Case of Giant Cell Arteritis.Cureus. 2022 Jul 1;14(7):e26483. doi: 10.7759/cureus.26483. eCollection 2022 Jul. Cureus. 2022. PMID: 35919218 Free PMC article.
-
Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers.Curr Rheumatol Rep. 2020 Nov 7;22(12):88. doi: 10.1007/s11926-020-00965-w. Curr Rheumatol Rep. 2020. PMID: 33159612 Review.
-
Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity.Autoimmun Rev. 2015 Apr;14(4):352-7. doi: 10.1016/j.autrev.2014.12.005. Epub 2014 Dec 17. Autoimmun Rev. 2015. PMID: 25528219 Review.
Cited by
-
Giant Cell Arteritis after COVID-19 Vaccination with Long-Term Follow-Up: A Case Report and Review of the Literature.Medicina (Kaunas). 2023 Dec 6;59(12):2127. doi: 10.3390/medicina59122127. Medicina (Kaunas). 2023. PMID: 38138230 Free PMC article. Review.
-
Increased vertebral canal diameter measured by ultrasonography as a sign of vasculitis in patients with giant cell arteritis.Front Med (Lausanne). 2023 Nov 7;10:1283285. doi: 10.3389/fmed.2023.1283285. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38020125 Free PMC article.
-
Incidence of biopsy-proven giant cell arteritis (GCA) in South Australia 2014-2020.Front Med (Lausanne). 2023 Apr 20;10:1173256. doi: 10.3389/fmed.2023.1173256. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37153092 Free PMC article.
-
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register.RMD Open. 2024 Mar 26;10(1):e003824. doi: 10.1136/rmdopen-2023-003824. RMD Open. 2024. PMID: 38531620 Free PMC article.
-
Giant cell arteritis: incidence and phenotypic distribution in Western Norway 2013-2020.Front Med (Lausanne). 2023 Dec 12;10:1296393. doi: 10.3389/fmed.2023.1296393. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38148911 Free PMC article.
References
-
- Abdul-Rahman AM, Molteno AC, Bevin TH. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. N Z Med J. (2011) 124:44–52. - PubMed
LinkOut - more resources
Full Text Sources